Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00084461
Other study ID # NCI-2012-01449
Secondary ID 0425NCI-6325OSU-
Status Terminated
Phase Phase 2
First received June 10, 2004
Last updated June 3, 2013
Start date March 2004

Study information

Verified date June 2013
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

Phase II trial to study the effectiveness of romidepsin in treating patients who have locally advanced or metastatic neuroendocrine tumors. Drugs used in chemotherapy, such as romidepsin, work in different ways to stop tumor cells from dividing so they stop growing or die.


Description:

PRIMARY OBJECTIVES:

I. Determine objective response rate in patients with locally advanced or metastatic neuroendocrine tumors treated with FR901288 (romidepsin).

SECONDARY OBJECTIVES:

I. Determine the toxicity of this drug in these patients. II. To measure serum tumor markers (pancreastatin, gastrin, pancreatic polypeptide, glucagon, substance-P, neurotensin, calcitonin, somatostatin, vasoactive intestinal peptide, gastrin releasing polypeptide, ACTH) depending on the tumor type pre-, during-, and post-treatment.

III. To perform a nuclear medicine functional imaging scan (octreoscan) to evaluate the disease status pre-, during-, and post-treatment.

IV. To perform histone acetylation assay in cytospins from peripheral blood mononuclear cells (PBMCs) to correlate with disease response and with immunologic parameters.

V. To quantify gene expression by Real Time PCR of type 1 and type 2 cytokines, co-stimulatory molecules, and adhesion molecules in PBMCs obtained from the pre-, during-, and post-treatment blood samples.

VI. To perform a multicolor flow cytometric analysis on fresh blood to assess activation of lymphocyte subsets and presence of co-stimulatory and adhesion molecules.

VII. To perform in vitro functional assays for innate as well as antigen-specific T cell immune responses in PBMCs obtained from the pre-, during-, and post-treatment blood samples.

OUTLINE:

Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving complete remission (CR) receive 2 additional courses beyond CR.

Patients are followed at 2-4 weeks.


Recruitment information / eligibility

Status Terminated
Enrollment 25
Est. completion date
Est. primary completion date October 2004
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologically confirmed carcinoid tumor or islet cell neuroendocrine tumor

- Well- or moderately-differentiated tumor

- Metastatic and/or locally advanced disease

- Measurable disease

- Unidimensionally measurable lesion at least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan

- Lesions in a previously irradiated area are not considered measurable

- No truly non-measurable lesions, including the following:

- Bone lesions

- Leptomeningeal disease

- Ascites

- Pleural or pericardial effusion

- Lymphangitis cutis/pulmonis

- Abdominal masses not confirmed and followed by imaging

- Cystic lesions

- Ineligible for standard treatment

- Performance status - ECOG 0-1

- At least 6 months

- WBC >= 3,000/mm^3

- Absolute neutrophil count >= 1,500/mm^3

- Platelet count >= 100,000/mm^3

- Bilirubin =< 1.5 mg/dL

- AST and ALT =< 2.5 times upper limit of normal

- Creatinine =< 1.5 mg/dL

- No New York Heart Association class III or IV congestive heart failure

- No myocardial infarction within the past year

- No uncontrolled dysrhythmias

- No poorly controlled angina

- No serious ventricular arrhythmia, defined as ventricular tachycardia or ventricular fibrillation >= 3 beats in a row

- No left ventricular hypertrophy by EKG

- No other significant cardiac disease

- QTc < 500 msec

- LVEF > 40% by resting MUGA

- No prior allergic reaction attributed to compounds of similar chemical or biological composition to study drug

- No ongoing or active infection

- No psychiatric illness or social situation that would preclude study compliance

- No other concurrent uncontrolled illness

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- More than 4 weeks since prior immunotherapy (e.g., interferon alfa)

- More than 4 weeks since prior chemotherapy

- More than 12 weeks since prior hepatic artery chemoembolization unless liver lesions are not the only indicator lesions

- No prior FR901228 (depsipeptide)

- No more than 1 prior systemic chemotherapy regimen for carcinoid or islet cell tumor (other than hepatic artery chemoembolization)

- More than 4 weeks since prior oral or IV steroids (first 16 patients only)

- Concurrent long-acting octreotide allowed at standard doses if dose has been stable for the past 12 weeks

- Concurrent subcutaneous octreotide for breakthrough use for symptomatic relief allowed

- No concurrent systemic steroids (first 16 patients only)

- More than 4 weeks since prior radiotherapy

- More than 4 weeks since prior investigational tumor-specific therapy

- No other prior histone deacetylase inhibitors (e.g., valproic acid)

- No concurrent hydrochlorothiazide

- No concurrent combination antiretroviral therapy for HIV-positive patients

- No other concurrent investigational or commercial agents or therapies for the malignancy

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
romidepsin
Given IV
Other:
laboratory biomarker analysis
Correlative studies

Locations

Country Name City State
United States Ohio State University Medical Center Columbus Ohio

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective response rate Frequency of response will be estimated with a 95% confidence interval. Up to 4 weeks No
Secondary Incidence of toxicity Up to 4 weeks Yes
See also
  Status Clinical Trial Phase
Recruiting NCT02021604 - Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma Phase 1
Withdrawn NCT02108782 - Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors Phase 2
Active, not recruiting NCT05034783 - [68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients Early Phase 1
Terminated NCT02273752 - Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Phase 2
Completed NCT00937079 - Whole Body 111In-exendin-4 Imaging Study in Insulinoma Patients Phase 1
Recruiting NCT04185350 - Clinical Evaluation of 68Ga-NOTA-MAL-Cys39-exendin-4 Positron Emission Tomography in the Detection of Insulinoma Early Phase 1
Recruiting NCT00001276 - Diagnosing and Treating Low Blood Sugar Levels
Active, not recruiting NCT02121366 - EUS-guided Ethanol Ablation of an Insulinoma N/A
Completed NCT00131911 - Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Phase 2
Completed NCT00005910 - Laparoscopy to Remove Pancreatic Tumors (Insulinomas) N/A
Recruiting NCT03583528 - DOTATOC PET/CT for Imaging NET Patients
Withdrawn NCT04915144 - 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs Phase 2
Recruiting NCT05523778 - A Multi-center Study to Evaluate the Efficacy and Safety of Pancreatic Duct Stents Placement Before the Enucleation of Insulinoma Located in the Head and Neck of the Pancreas Near the Main Pancreatic Duct N/A
Recruiting NCT02560376 - 68Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis Phase 0
Completed NCT01525082 - Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors Phase 2
Completed NCT00655655 - Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors Phase 1
Completed NCT00075439 - Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Phase 2
Terminated NCT04452396 - CGM (Continuous Glucose Monitoring) Use in Diagnosis of Spontaneous and Reactive Hypoglycaemia N/A
Active, not recruiting NCT01824875 - Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors Phase 2
Completed NCT00004074 - Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Phase 1